GB9711115D0 - Integrin-targeting vectors having enhanced transfection activity - Google Patents

Integrin-targeting vectors having enhanced transfection activity

Info

Publication number
GB9711115D0
GB9711115D0 GBGB9711115.7A GB9711115A GB9711115D0 GB 9711115 D0 GB9711115 D0 GB 9711115D0 GB 9711115 A GB9711115 A GB 9711115A GB 9711115 D0 GB9711115 D0 GB 9711115D0
Authority
GB
United Kingdom
Prior art keywords
integrin
transfection activity
targeting vectors
enhanced transfection
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9711115.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Institute of Child Health
Original Assignee
UCL Institute of Child Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Institute of Child Health filed Critical UCL Institute of Child Health
Priority to GBGB9711115.7A priority Critical patent/GB9711115D0/en
Publication of GB9711115D0 publication Critical patent/GB9711115D0/en
Priority to AU76673/98A priority patent/AU7667398A/en
Priority to CA002288840A priority patent/CA2288840A1/en
Priority to AT98924478T priority patent/ATE301722T1/de
Priority to JP55077198A priority patent/JP4293292B2/ja
Priority to PCT/GB1998/001577 priority patent/WO1998054347A1/en
Priority to DE69831156T priority patent/DE69831156T2/de
Priority to EP98924478A priority patent/EP1003898B1/en
Priority to US09/424,656 priority patent/US6458026B1/en
Priority to US10/137,435 priority patent/US20030013644A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrotherapy Devices (AREA)
GBGB9711115.7A 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity Pending GB9711115D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB9711115.7A GB9711115D0 (en) 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity
US09/424,656 US6458026B1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity
JP55077198A JP4293292B2 (ja) 1997-05-29 1998-05-29 トランスフェクション活性を有するインテグリン−ターゲッティングベクター
CA002288840A CA2288840A1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity
AT98924478T ATE301722T1 (de) 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität
AU76673/98A AU7667398A (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity
PCT/GB1998/001577 WO1998054347A1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity
DE69831156T DE69831156T2 (de) 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität
EP98924478A EP1003898B1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity
US10/137,435 US20030013644A1 (en) 1997-05-29 2002-05-03 Integrin-targeting vectors having transfection activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711115.7A GB9711115D0 (en) 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity

Publications (1)

Publication Number Publication Date
GB9711115D0 true GB9711115D0 (en) 1997-07-23

Family

ID=10813246

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9711115.7A Pending GB9711115D0 (en) 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity

Country Status (9)

Country Link
US (2) US6458026B1 (cg-RX-API-DMAC7.html)
EP (1) EP1003898B1 (cg-RX-API-DMAC7.html)
JP (1) JP4293292B2 (cg-RX-API-DMAC7.html)
AT (1) ATE301722T1 (cg-RX-API-DMAC7.html)
AU (1) AU7667398A (cg-RX-API-DMAC7.html)
CA (1) CA2288840A1 (cg-RX-API-DMAC7.html)
DE (1) DE69831156T2 (cg-RX-API-DMAC7.html)
GB (1) GB9711115D0 (cg-RX-API-DMAC7.html)
WO (1) WO1998054347A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5043271B2 (ja) 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
EP1285081A2 (en) * 2000-05-30 2003-02-26 ICH Productions Limited Improved methods of transfection
EP1178117A1 (en) * 2000-08-02 2002-02-06 Erasmus Universiteit Rotterdam Targeting through integrins
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
GB0106315D0 (en) 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
KR100904954B1 (ko) * 2001-05-30 2009-06-26 더 스크립스 리서치 인스티튜트 핵산용 전달 시스템
CN1622830A (zh) 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
KR20060015534A (ko) * 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
MX2008009970A (es) * 2006-02-01 2008-11-19 Univ Johns Hopkins Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos.
US10034674B2 (en) * 2006-02-02 2018-07-31 Steven C Chudik Universal anterior cruciate ligament repair and reconstruction system
GB0610636D0 (en) 2006-05-30 2006-07-05 Univ London Materials and complexes for the delivery of biologically-active material to cells
EP2178896A1 (en) * 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2009094634A1 (en) 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
JP2012513589A (ja) 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド 骨髄イメージング剤としての99mTc−ペプチド系化合物の応用
EP4710943A3 (en) 2015-08-28 2026-04-29 Molecular Transfer, Inc. Transfection complexes and methods of using the same
WO2017151733A1 (en) 2016-03-01 2017-09-08 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells
GB201803419D0 (en) * 2018-03-02 2018-04-18 Ucl Business Plc Complex for the delivery of cas9 proteins guide RNA to cells
US12649000B2 (en) 2018-03-19 2026-06-09 Algipharma As Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
DE69536153D1 (de) 1994-11-17 2011-05-05 Ich Productions Ltd Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery

Also Published As

Publication number Publication date
EP1003898B1 (en) 2005-08-10
CA2288840A1 (en) 1998-12-03
DE69831156T2 (de) 2006-06-08
DE69831156D1 (de) 2005-09-15
US6458026B1 (en) 2002-10-01
ATE301722T1 (de) 2005-08-15
JP4293292B2 (ja) 2009-07-08
EP1003898A1 (en) 2000-05-31
US20020042384A1 (en) 2002-04-11
WO1998054347A1 (en) 1998-12-03
AU7667398A (en) 1998-12-30
US20030013644A1 (en) 2003-01-16
JP2002502243A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
AU7667398A (en) Integrin-targeting vectors having transfection activity
CA2166931A1 (en) Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon
EP0981874A4 (en) OPTIMALLY OPERATIONAL, PROACTIVE CRYPTOSYSTEM WITH PUBLIC KEY AND RELATED METHOD
AU5228399A (en) System for generating, distributing and receiving an interactive user interface
AU3739697A (en) Gene delivery system
AU5153296A (en) Vectors for gene delivery
EP1019028A4 (en) $ I PROTEIN (CHLAMYDIA), GENE SEQUENCE, AND USES THEREOF
PL327984A1 (en) Complementary systems of adenoviral vectors and cell lines
AU5671096A (en) Methods, nucleotide sequences and host cells for assaying ex ogenous and endogenous protease activity
AU5044300A (en) Methods, concepts and technology for a virtual shopping system capable of assessing needs of a customer and recommending a product or service based on such assessed needs
ZA9810396B (en) Fuel dispensing system.
AU5849498A (en) Data card verification system
HUP9700428A3 (en) Targetcell-specific vectors for inserting genes, pharmaceuticals comprising such vectors and their use
AU7360498A (en) Communications system for delivering promotional messages
AU2445795A (en) An enzyme with endo-1,3(4)-beta -glucanase activity
AU7908298A (en) Endo-beta-1,4-glucanases from (saccharothrix)
AP2002002546A0 (en) Iron chelator delivery system.
CA2281206A1 (en) Geranyl diphosphate synthase genes
AU6028898A (en) Methods for cultivating cells and propagating viruses
AU8620698A (en) Antifreeze proteins, dna and expression systems
GB9724143D0 (en) Pharmaceutical conjugate
AUPO474997A0 (en) Distribution system with authentication
AU3877395A (en) Enzyme gene therapy catalysing prodrug extracellular conversion
CA2302551A1 (en) .beta.-fructofuranosidase and its gene
NZ311175A (en) Gene preparation comprising a gene incorporated into a biocompatible carrier which preferably contains collagen